首页> 外文期刊>Biochemical Pharmacology >The antiplatelet activity of magnolol is mediated by PPAR-β/γ
【24h】

The antiplatelet activity of magnolol is mediated by PPAR-β/γ

机译:厚朴酚的抗血小板活性由PPAR-β/γ介导

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Activation of peroxisome proliferator-activated receptor (PPAR) isoforms (α, β/δ, and γ) is known to inhibit platelet aggregation. In the present study, we examined whether PPARs-mediated pathways contribute to the antiplatelet activity of magnolol, a compound purified from Magnolia officinalis. Magnolol (20-60 μM) dose-dependently enhanced the activity and intracellular level of PPAR-β/γ in platelets. In the presence of selective PPAR-β antagonist (GSK0660) or PPAR-γ antagonist (GW9662), the inhibition of magnolol on collagen-induced platelet aggregation and intracellular Ca 2+ mobilization was significantly reversed. Moreover, magnolol-mediated up-regulation of NO/cyclic GMP/PKG pathway and Akt phosphorylation leading to increase of eNOS activity were markedly abolished by blocking PPAR-β/γ activity. Additionally, magnolol significantly inhibited collagen-induced PKCα activation through a PPAR-β/γ and PKCα interaction manner. The arachidonic acid (AA) or collagen-induced thromboxane B 2 formation and elevation of COX-1 activity caused by AA were also markedly attenuated by magnolol. However, these above effects of magnolol on platelet responses were strongly reduced by simultaneous addition of GSK0660 or GW9662, suggesting that PPAR-β/γ-mediated processes may account for magnolol-regulated antiplatelet mechanisms. Similarly, administration of PPAR-β/γ antagonists remarkably abolished the actions of magnolol in preventing platelet plug formation and prolonging bleeding time in mice. Taken together, we demonstrate for the first time that the antiplatelet and anti-thrombotic activities of magnolol are modulated by up-regulation of PPAR-β/γ-dependent pathways.
机译:过氧化物酶体增殖物激活受体(PPAR)同工型(α,β/δ和γ)的激活可抑制血小板聚集。在本研究中,我们检查了PPAR介导的途径是否对厚朴酚(一种从厚朴提取的化合物)的抗血小板活性有贡献。厚朴酚(20-60μM)剂量依赖性地增强血小板中PPAR-β/γ的活性和细胞内水平。在存在选择性PPAR-β拮抗剂(GSK0660)或PPAR-γ拮抗剂(GW9662)的情况下,厚朴酚对胶原蛋白诱导的血小板聚集和细胞内Ca 2+动员的抑制作用显着逆转。此外,通过阻断PPAR-β/γ活性,明显消除了厚朴酚介导的NO /环GMP / PKG途径的上调和导致eNOS活性增加的Akt磷酸化。此外,厚朴酚还通过PPAR-β/γ和PKCα相互作用的方式显着抑制胶原诱导的PKCα活化。厚朴酚也显着减弱了花生四烯酸(AA)或胶原诱导的血栓烷B 2的形成以及由AA引起的COX-1活性的升高。但是,通过同时添加GSK0660或GW9662,强烈降低了厚朴酚对血小板反应的上述影响,这表明PPAR-β/γ介导的过程可能是厚朴酚调节的抗血小板机制的原因。同样,施用PPAR-β/γ拮抗剂可显着消除厚朴酚在预防血小板栓塞形成和延长小鼠出血时间方面的作用。两者合计,我们首次证明了厚朴酚的抗血小板和抗血栓形成活性是通过上调PPAR-β/γ依赖性途径来调节的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号